Several observational studies have shown that low serum levels of adiponectin are inversely associated with the risk of developing hormone-dependent tumors, as well as breast, cervical, endometrial, ovarian, and prostate cancers [11]. The gene discussed is ADIPOQ; the disease is prostate carcinoma.